Proteasome inhibition in maintenance therapy
Where does proteasome inhibition fit in the maintenance treatment paradigm?
Professor Graham Jackson and Professor Meletios Dimopoulos discuss the influence of continuous proteasome inhibitor treatment as a maintenance strategy in newly diagnosed multiple myeloma and the latest evidence from clinical trials in this treatment landscape.
Interview following a Takeda symposium. The views expressed in the video are those of the speakers.